SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Head And Neck Cancer: Likelihood of Approval

As Edge­wise Ther­a­peu­tics works to­wards its first FDA drug ap­proval, the small bio­phar­ma is al­ready launch­ing re­sources for one of the rare dis­ease com­mu­ni­ties it

Image credit: Shutterstock/aceshot1 There is an increasing number of high-concentration mAbs among approved therapeutics, with 76% of US Food and Drug Administration (FDA)-approved mAbs having high